AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02467049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULTRASOUND-guided insertion of PICC
Description: Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
Study NCT01951261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring and telephone control
Description: Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
Study NCT02730676 — intervention group
Intervention type: OTHER
Intervention: Electronic Cigarette #1
Description: VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
Study NCT02730676 — intervention group
Intervention type: OTHER
Intervention: Electronic Cigarette #2
Description: VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
Study NCT00983424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Description: dose escalation, administered orally twice a day
Study NCT00983424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/m2 IV days 1, 8 and 15
Study NCT04161547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 100 mg; Matching placebo 100 mg
Description: CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
Study NCT04161547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 200 mg; Matching placebo 200 mg
Description: CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
Study NCT04161547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 400 mg; Matching placebo 400 mg
Description: CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
Study NCT04161547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 600 mg; Matching placebo 600 mg
Description: CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
Study NCT03223714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept Ophthalmic Injection
Description: Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11).
Study NCT03223714 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conbercept Ophthalmic Injection
Description: Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11).
Study NCT03223714 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11).
Study NCT03469180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
Study NCT05336292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life-focused intervention
Description: The intervention works different skills to increase the meaningful life in the general population and specifically in the army.
Study NCT05336292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life and emotional regulation-focused intervention
Description: The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.
Study NCT05336292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group does not do any intervention
Study NCT03008993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HQIS implementation
Study NCT04364113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Protein Diet
Description: The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
Study NCT04364113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Protein Diet
Description: The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
Study NCT04364113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Diet
Description: The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
Study NCT04364113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein Diet
Description: The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
Study NCT04364113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Protein Diet
Description: The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
Study NCT00078858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00078858 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00078858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBMC transplantation
Study NCT00078858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBMC transplantation
Study NCT00078858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study NCT04364113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications needed to maintain usual blood pressure
Description: The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
Study NCT04364113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medications needed to maintain usual blood pressure
Description: The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
Study NCT04364113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications needed to maintain low blood pressure
Description: The MAP goal for the low blood pressure group is \<=92 mm Hg for ages 18-60 and \<=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
Study NCT02240069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education (Tx1)
Description: Education on best burn practices
Study NCT02240069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Filtration Unit Treatment (Tx2)
Description: A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove
Study NCT02240069 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Intervention (Tx3)
Description: A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter.
Study NCT03228316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superior hypogastric plexus block
Description: nerve plexus block
Study NCT03228316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency
Description: pulsed radiofrequency on sacral nerve roots 2,3 and 4
Study NCT02387528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1- Mindfulness Intervention
Description: An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
Study NCT02387528 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 2- Relaxation Intervention
Description: Eight meetings where the participants will practice relaxation techniques.
Study NCT02387528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3- Wait List Control Group
Description: No intervention
Study NCT01848743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Study NCT01848743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lamivudine
Study NCT01883947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Touch massage
Description: Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
Study NCT01883947 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-TENS
Description: Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
Study NCT01447927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO QD and BID
Study NCT01447927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO QD and BID
Study NCT02468128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebacoyl Dinalbuphine Ester
Description: Intramuscular injection 2mL/vial (75mg/mL)
Study NCT02468128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
Study NCT00640653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence-only HIV/STD risk-reduction intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
Study NCT00640653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer-sex-only HIV/STD risk-reduction intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
Study NCT00078858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO or IV
Study NCT00078858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00640653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long comprehensive HIV/STD risk-reduction intervention
Description: Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
Study NCT00640653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short comprehensive HIV/STD risk-reduction intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
Study NCT00640653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion control intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention.
Study NCT03644836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: Sweet taste cocoa flavored drink
Study NCT03644836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sweet taste cocoa flavored drink
Study NCT03482791 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Description: * The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~* The Mevion S-250 Proton Radiation Beam Therapy System will be used.
Study NCT03482791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measures
Description: -Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
Study NCT04608344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered as single dose tablet orally.
Study NCT04608344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Administered as single dose tablet orally.
Study NCT04596241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
Study NCT01861795 — intervention group
Intervention type: OTHER
Intervention: Preterm Neonates
Description: Preterm Neonates
Study NCT03936075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Guided Imagery and Music method
Description: the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills
Study NCT03936075 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard care and verbal counselling
Description: the participants receive their usual cancer treatment and two individual counselling sessions
Study NCT03277417 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Imaging of fetal heart and amniotic fluid
Study NCT03877952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-CORT125281
Description: 14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
Study NCT01747837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Vessix Renal Denervation System
Description: Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts
Study NCT04608344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered as single dose tablet orally.
Study NCT04608344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Administered as tablet orally once daily for 11 days.
Study NCT02103335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
Study NCT02103335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marizomib
Description: IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
Study NCT02103335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose dexamethasone
Description: Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
Study NCT03660475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone formulated as ophthalmic solution
Study NCT03660475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo ophthalmic solution
Study NCT00232596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
Study NCT00232596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study NCT01238562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study NCT01238562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study NCT01238562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study NCT01238562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
Study NCT01238562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study NCT02089100 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Study NCT02089100 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Systemic treatment
Study NCT02089100 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Systemic treatment